Traws Pharma, Inc.
TRAW·NasdaqCM·Healthcare
0.2686−0.0334 (−11.06%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD
After hours0.2850+0.0164 (+6.11%)Nov 4, 5:52 PM EST
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close0.3020
Open0.3000
Day range0.25850.3090
52-week range0.25853.2300
Off day high−13.07%
Off 52-week high−91.68%
Volume101.63K
Avg. volume (3M)580.49K
Market cap4.13M
EPS (TTM)-1.71
Forward P/E-0.14
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)1.53
Shares outstanding15.37M
Short interest5.25% of float
Earnings dateAug 14, 2025 (est.)
Analyst target1.0000
Profit margin0.00%
Against its peers
Compare in full ›| TRAW | COCP | TOVX | NIKI | PCSA | TVGN | |
|---|---|---|---|---|---|---|
| Market cap | 4.13M | 19.46M | 8.72M | 5.27M | 5.41M | 95.87M |
| P/E (TTM) | — | — | 0.3 | — | — | — |
| Forward P/E | -0.1 | -2.1 | -1.0 | — | -0.5 | — |
| Price/book | 2.4 | 13.3 | 0.7 | 0.1 | -17.0 | -1.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −86.18% | +2.88% | −40.00% | −87.43% | −77.18% | −77.45% |
| Today | −11.06% | −5.61% | +4.40% | −3.98% | −0.26% | −3.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TRAW news ›Traws Pharma, Inc. (NASDAQ:TRAW) Stock Rated “Reduce” by Sell-Side Analysts
Posted by Mitch Edgeman on Oct 23rd, 2026 A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a research report…
From the 4Search news index, newest first.
In the news
1mentions in 30 days
1with it in the headline
Negativesentiment
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.